November 26, 2020

CLASS ACTION UPDATE for NXTC, GOCO and FLDM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

The MarketWatch News Department was not involved in the creation of this content.

September 23, 2020 (ACCESSWIRE via COMTEX) —
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

NXTC Shareholders Click Here: https://www.zlk.com/pslra-1/nextcure-inc-information-request-form?prid=9549&wire=1GOCO Shareholders Click Here: https://www.zlk.com/pslra-1/gohealth-inc-information-request-form?prid=9549&wire=1FLDM Shareholders Click Here: https://www.zlk.com/pslra-1/fluidigm-corporation-information-request-form?prid=9549&wire=1

* ADDITIONAL INFORMATION BELOW *

Nextcure, Inc. (NASDAQ:NXTC)

The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company’s secondary public offering declared effective on November 14, 2019.Lead Plaintiff Deadline: November 20, 2020TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/nextcure-inc-information-request-form?prid=9549&wire=1

Throughout the class period, defendants’ statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.

GoHealth, Inc. (NASDAQ:GOCO)

The GoHealth lawsuit is on behalf of all purchasers of GoHealth Class A common stock pursuant and/or traceable to the registration statement issued in connection with GoHealth’s July 2020 initial public offering.Lead Plaintiff Deadline: November 20, 2020TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/gohealth-inc-information-request-form?prid=9549&wire=1

According to the filed complaint, (i) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (ii) GoHealth suffered from a higher risk of customer churn as a result of its unique business model and limited carrier base; (iii) GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company’s concentrated carrier business model, and GoHealth’s efforts to expand into new geographies, develop new carrier partnerships and worsening product mix; (iv) GoHealth had entered into materially less favorable revenue-sharing arrangements with its external sales agents; and (v) these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the initial public offering.

Fluidigm Corporation (NASDAQ:FLDM)

FLDM Lawsuit on behalf of: investors who purchased February 7, 2019 – November 5, 2019Lead Plaintiff Deadline: November 20, 2020TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fluidigm-corporation-information-request-form?prid=9549&wire=1

According to the filed complaint, during the class period, Fluidigm Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) Fluidigm was experiencing longer sales cycles; (2) as a result, Fluidigm’s revenue was reasonably likely to decline; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington, D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.55 Broadway, 10th FloorNew York, NY [email protected]: (212) 363-7500Fax: (212) 363-7171http://www.zlk.com

SOURCE: Levi & Korsinsky, LLP

View source version on accesswire.com: https://www.accesswire.com/607513/CLASS-ACTION-UPDATE-for-NXTC-GOCO-and-FLDM-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

COMTEX_371767857/2457/2020-09-23T17:37:53

Is there a problem with this press release? Contact the source provider Comtex at [email protected] You can also contact MarketWatch Customer Service via our Customer Center.

Copyright 2020 ACCESSWIRE

The MarketWatch News Department was not involved in the creation of this content.

Source Article